Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Génito-urinaire du Quebec-led Phase 3 Trial.

Autor: Niazi T; Jewish General Hospital, McGill University, Montreal, Quebec, Canada. Electronic address: tniazi@jgh.mcgill.ca., Nabid A; Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada., Malagon T; Department of Oncology, McGill University, Montréal, Quebec, Canada; St Mary's Research Centre, Montréal West Island CIUSSS, Montréal, Quebec, Canada., Tisseverasinghe S; Hôpital de Gatineau, Gatineau, Quebec, Canada., Bettahar R; Centre Hospitalier Régional de Rimouski-Centre de Cancer, Rimouski, Quebec, Canada., Dahmane R; Pavillon Ste-Marie Centre Hospitalier Régional de Trois-Rivières (CHRTR), Trois-Rivières, Quebec, Canada., Martin AG; Centre Hospitalier Universitaire de Québec (CHUQ)-L'Hôtel-Dieu de Québec, Quebec City, Quebec, Canada., Jolicoeur M; Hôpital Charles LeMoyne, Greenfield Park, Quebec, Canada., Yassa M; Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada., Barkati M; Centre Hospitalier de l'Université de Montréal (CHUM) (MB), Montreal, Quebec, Canada., Igidbashian L; Hôpital Cité-de-la-Santé, Laval, Quebec, Canada., Bahoric B; Jewish General Hospital, McGill University, Montreal, Quebec, Canada., Archambault R; Hôpital de Gatineau, Gatineau, Quebec, Canada., Villeneuve H; Hôpital de Chicoutimi, Chicoutimi, Quebec, Canada., Mohiuddin M; Saint John Regional Hospital (MM), Saint John, New Brunswick, Canada.

Publikováno v: European urology [Eur Urol] 2024 Sep 12. Date of Electronic Publication: 2024 Sep 12.

Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial.

Autor: Niazi T; Department of Oncology, Division of Radiation Onclogy, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada. Electronic address: mohammad.niazi@mcgill.ca., Nabid A; Department of Oncology, Division of Radiation Onclogy, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada., Malagon T; Department of Oncology, McGill University, Montreal, Quebec, Canada., Bettahar R; Division of Radiation Onclogy, Centre Hospitalier Régional de Rimouski-Centre de Cancer, Rimouski, Quebec, Canada., Vincent L; Division of Radiation Onclogy, Pavillon Ste-Marie Centre Hospitalier Régional de Trois-Rivières, Trois-Rivières, Quebec, Canada., Martin AG; Department of Oncology, Division of Radiation Onclogy, Centre Hospitalier Universitaire de Québec-L'Hôtel-Dieu de Québec, Quebec City, Quebec, Canada., Jolicoeur M; Department of Oncology, Division of Radiation Onclogy, Hôpital Charles LeMoyne, Greenfield Park, Quebec, Canada., Yassa M; Department of Oncology, Division of Radiation Onclogy, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada., Barkati M; Department of Oncology, Division of Radiation Onclogy, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada., Igidbashian L; Division of Radiation Onclogy, Hôpital Cité-de-la-Santé, Laval, Quebec, Canada., Bahoric B; Department of Oncology, Division of Radiation Onclogy, Jewish General Hospital, McGill University, Quebec, Canada., Archambault R; Department of Oncology, Division of Radiation Onclogy, Hôpital Gatineau, Gatineau, Quebec, Canada., Villeneuve H; Department of Oncology, Division of Radiation Onclogy, Hôpital de Chicoutimi, Chicoutimi, Quebec, Canada., Tsui JMG; Department of Oncology, Division of Radiation Onclogy, McGill University Health Centre, Montreal, Quebec, Canada., Mohiuddin M; Department of Oncology, Division of Radiation Onclogy, Saint John Regional Hospital (MM), Saint John, New Brunswick, Canada.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 Jan 01; Vol. 118 (1), pp. 52-62. Date of Electronic Publication: 2023 May 22.

Biochemical Recurrence is Not a Surrogate for Overall Survival in Localized Prostate Cancer: Data from 2 Phase III Trials

Autor: Nabid, A., Carrier, N., Vigneault, E., Martin, A.G., Nguyen, T.V., Bahary, J.P., Vavassis, P., Bahoric, B., Brassard, M.A., Vass, S.T., Jr, Archambault, R., Vincent, F., Bettahar, R., Duclos, M., Wilke, D.R., Souhami, L.

Publikováno v: In International Journal of Radiation Oncology, Biology, Physics 1 October 2024 120(2) Supplement:e566-e566

P066 - Outcomes after biochemical failure in high risk prostate cancer. Long-term data from a phase III trial

Autor: Nabid, A., Carrier, N., Martin, A-G., Bahary, J-P., Vavassis, P., Vass, S., Bahoric, B., Archambault, R., Vincent, F., Bettahar, R., Souhami, L.

Publikováno v: In European Urology Open Science November 2023 57 Supplement 1:S98-S99

Patient Reported Outcomes in High-Risk Prostate Cancer Patients with or without Testosterone Recovery after Androgen Deprivation Therapy

Autor: Nabid, A., Carrier, N., Martin, A.G., Bahary, J.P., Vavassis, P., Vass, S.T., Jr, Bahoric, B., Archambault, R., Vincent, F., Bettahar, R., Souhami, L.

Publikováno v: In International Journal of Radiation Oncology, Biology, Physics 1 October 2023 117(2) Supplement:S95-S96